Private Equity 3 Days

Last updated: May 27, 2026, 11:30 AM ET

Deal Activity & Capital Deployments DigitalBridge announced a $1.05bn acquisition of ArcLight, blending a $650 m cash payment with up to $400 m of earn‑out consideration, a move that expands its edge‑computing footprint in North America. At the same time, CVC Capital Partners completed a €4bn sale of its 13.8% stake in Naturgy, ending an eight‑year holding and delivering a sizable cash return to its Dutch pension backers. In Europe, Modella Capital secured the purchase of Flying Tiger Copenhagen, marking the firm’s most ambitious high‑street roll‑up as it seeks to create a pan‑European retail platform. Across the Atlantic, I Squared Capital pledged up to $1bn to launch a U.S. AI‑inference data‑centre platform, underscoring private equity’s growing appetite for specialised infrastructure that supports generative‑AI workloads.

Impact‑Focused Capital Strategies During the PEI Group Impact Investor Global Summit, panelists warned that impact‑oriented limited partners are adding a new diligence layer to portfolio company CVs to protect mission alignment, a practice that could become a de‑facto standard for ESG‑driven funds. Reinforcing that trend, APG outlined a €10bn impact‑private‑equity target, expanding its responsible‑investment mandate and signalling that large pension funds are willing to allocate material capital to socially‑beneficial assets. The shift is echoed in the placement‑agent space, where PEI’s latest ranking showed placement firms raised $82bn for GP clients in 2024, reflecting robust capital‑raising pipelines for impact‑focused strategies.

Mid‑Market Platform Consolidation Carlyle appointed Ian Fujiyama as chairman of its US/Europe mid‑market platform and simultaneously highlighted attractive opportunities in ADG services, citing rising government demand for cyber and AI‑enabled defence technologies. The firm’s strategic focus aligns with Carlyle’s broader push into health‑care, evident in the GHO‑CBC merger that will create the world’s largest healthcare‑focused PE investor. Parallel moves include Omni Partners bringing on Roald Hunvik as its first partner outside the UK, expanding its Scandinavian footprint, and Lovell Minnick‑backed Xactus acquiring a new subsidiary to operate as Xeda Link, a step that broadens its portfolio of niche industrial services.

Credit & Debt Market Moves CPP Investments reported C$793.3bn in assets, with private‑equity exposure at 22% of its fund mix, highlighting the sovereign fund’s continued reliance on illiquid credit. In contrast, JPMorgan is seeking to offload more than $4bn of NAV loans to private‑equity funds, a move that could free balance‑sheet capacity while shifting risk to third‑party investors. Meanwhile, CVC Credit refreshed its backing of Curium with a combined debt‑equity refinancing package, ensuring liquidity for the nuclear‑medicine specialist amid tightening capital markets. On the asset‑based lending front, PGIM deployed roughly $4bn into U.S. residential land‑banking transactions, illustrating the persistence of real‑estate‑linked credit despite higher rates.

Fundraising & GP Activity Seine Capital closed its debut fund 20% above target, signaling strong investor appetite for secondaries expertise. Across the Atlantic, Eurazeo secured over €1bn at the first close of its PME V mid‑market buyout vintage, matching the size of its predecessor and reinforcing confidence in European mid‑cap opportunities. In the UK, Ardian promoted Mark Benedetti to co‑CEO, cementing leadership continuity as the firm navigates a competitive fundraising environment. Finally, Placement agents continued to dominate capital flows, with the top tier generating $82bn in new commitments, underscoring the importance of intermediaries in matching limited partners with high‑growth general partners.

Sector‑Specific Investments Blackstone Life Sciences entered a strategic financing partnership with Apogee Therapeutics, offering up to $1.3bn of royalty and debt capital, a deal that illustrates the deep‑pocketed support for late‑stage biotech. In the software arena, Hg invested $500 m in Rightsline, a rights‑and‑royalties management platform, while Main Capital‑backed Xait acquired Germany’s SAE for its CPQ and variant‑management suite, sharpening its foothold in enterprise Saa S. The industrial side saw Fortress acquire IPValue, a licensing firm with a portfolio of over 20,000 patents, expanding its intellectual‑property revenue stream. Lastly, New Mountain‑backed Swoop bought prescription‑management platform Nimble, adding a digital health tool to its portfolio as tele‑pharmacy demand accelerates.